EdgeBio will begin accepting clinical samples immediately for its first CLIA based test, the Clinical Exome Test, featuring whole exome sequencing.
“This marks the next phase of the natural evolution of our sequencing operations at EdgeBio,” said Dean Gaalaas, President and CEO of EdgeBio. “For the past three years we have been building expertise in both the generation and analysis of data via NGS in a research setting. Receiving CLIA certification now allows us to leverage this expertise to help clinicians better diagnose and treat their patients.”
EdgeBio, founded in 1990, has been a pioneer in DNA sequencing for over two decades. The company launched its sequencing and bioinformatics services in 2009 and has sequenced over 3500 samples to date. Dr. Sherri Bale, FACMG, of GeneDx, will serve as Laboratory Director for CLIA Operations. Dr. Bale is a Board-Certified Ph.D. Medical Geneticist, and a Founding Member of the American College of Medical Genetics. She has more than 30 years of experience in clinical, cytogenetic, and molecular genetics research and has authored over 130 papers, book chapters, and books in the field.